Introduction: Depression is a common reason for patients to consult homeopaths. This review aims
INTRODUCTION
Depression is the third most common burden of disease worldwide and is expected to become the leading burden of disease by 2030 [1] . The National Institute for Health and Clinical Excellence primarily recommends non-medical interventions such as cognitive behavioural therapy in subthreshold, mild and moderate depression as the first line treatment [2] . If these interventions are ineffective or the depression is severe, antidepressant drugs are recommended. These treatment options help some but not all patients, there is concern about the overuse of psychotropic drugs, and insufficient alternatives. Some patients seek complementary and alternative medicine (CAM) treatment options, and depression and other mental health problems are among the most common reasons why patients seek homeopathy [3, 4] . Homeopathy is controversial in some quarters, but despite this there is widespread use. A recent systematic review of 12-month prevalence of homeopathy use in eleven countries (USA, UK, Australia, Israel, Canada, Switzerland, Norway, Germany, South Korea, Japan and Singapore) found that a small but significant percentage of these general populations consulted homeopaths and/or purchased over-the-counter homeopathic medicines There is a need to assess the existing research evidence for homeopathy in depression due to the prevalence of depression in all countries worldwide, the limited effect of existing recommended interventions, and the fact that patients use homeopathy as an alternative or a complement to A C C E P T E D M A N U S C R I P T conventional treatment. One systematic review assessing research evidence for homeopathy in depression concluded that there was limited evidence due to a lack of high quality trials [7] . Another review on homeopathy in psychiatric conditions, which included only randomised placebo-controlled trials found none reporting on depression [8] . The aim of this review is to update these previous reviews and to assess the evidence for the efficacy, effectiveness and safety of homeopathy in patients with depression. The first draft of this updated review was published in the first author's (PV) PhD Thesis [9] . This article presents the results of our updated review.
METHODS

Search strategy
A systematic search of 30 databases and other sources was carried out, including e.g. CINAHL,
Cochrane Library, EMBASE, PubMed/MEDLINE, and PsycINFO (supplementary material, appendix A). Literature searches were carried out by one researcher (PV) from 9 to 12.08.2012, with update searches on 15.11.2013 and 05.07.2016. A second researcher (PF) checked all searches and found them to be appropriate. Screening of all articles (at titles/abstract and full-text level) was carried out by both researchers. Reference lists were checked and 44 researchers in 19 countries were contacted to identify additional titles.
Inclusion criteria were studies reporting on homeopathic treatment of patients with diagnosed or selfreported depression between 1982 and July 2016. In a previous extensive literature search, the authors found that most homeopathy trials were published after 1982, and none published prior to 1982 reported on mental health problems [10] . We therefore limited our search to studies published after 1982. This date also coincides with the time when selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants to date, came onto the market. No language limitations were set. Exclusion criteria were studies not reporting outcomes in patients suffering from depression as the primary focus; bipolar disorder; HMPs used in anthroposophical medicine, administered as injections or concentrations higher than 1:10,000 or one 100 th of the smallest dose used in conventional drugs (and therefore not available without a prescription in EU/EEA countries); animal studies; studies with less than 10 participants; conference abstracts; and reports presented in books.
Search strategies were adapted to each database, using variations of the words "homeopathy,"
"homeopathic drugs," "potentised," "depression," "depressive disorder," "dysthymia" and "dysthymic disorder", using wildcard symbols, and Boolean operators to combine terms.
The PICO may be describes as follows: Participants were patients with diagnosed or self-reported depression. The intervention was treatment provided by homeopaths or use of homeopathic medicinal products (HMPs). The comparator could be placebo, other depression medication or other depression treatment, waiting list, or no comparator. Outcomes were primary outcomes focusing on depression.
Data extraction and analysis
Articles were translated where necessary (Farsi n=1, Portuguese n=1, Spanish n=1). Data were extracted, appraised and analysed by one author (PV) and checked by a second (PF). Consensus of understanding was reached for all studies.
Data extracted from identified articles were input according to the Cochrane Consumers and
Communication Review Group's data extraction template. Risk of bias was assessed according to the Cochrane Collaboration's guidelines, focusing on the main outcome measure for each trial [11] .
Within-study publication bias, also referred to as outcome reporting bias or selective reporting bias, was reported for each included study. We also considered the potential risk of between-study publication bias. Controlled and uncontrolled studies were reported according to the STROBE statement [12] . We planned to carry out a meta-analysis in the event that the results of at least two trials could be presented at an aggregated level. This was however not carried out as we only found analysable data from two trials of which one was a non-inferiority trial and the other a superiority
trial.
An important question when assessing research evidence is whether individual studies provide the "best possible" outcome that could be expected with the tested intervention in the particular field of
research. An assessment of the model validity of studies, the degree to which the design and setting corresponds to "best practice" [13] , was therefore determined using recommendations put forward by Mathie et al. [14] .
Type of studies
The identified studies were categorised into three groups and described separately: those assessing the efficacy of HMPs; those assessing the effectiveness of treatment by homeopaths; and those describing the outcomes of patients treated by homeopaths.
Randomised double-blinded placebo-controlled trials were used to assess the efficacy of HMPs. To assess the effectiveness of treatment provided by homeopaths (consultations and HMPs), non-blinded randomised controlled trials (RCTs) and observational studies (cohort and case control studies) were
used. Uncontrolled studies (UCs) (including surveys) were used to assess outcomes during and after treatment, but not as evidence of causal links. Where possible, results were reported in an aggregated form, summarising outcomes for more than one study. Where p-values were reported, ≤ 0.05 was considered statistically significant. To assess the safety of homeopathy, adverse event reporting from all three groups was considered.
RESULTS
Search results
Thirty databases and other sources identified 3,692 titles. After addition of 31 titles identified through reference lists (n=24), contact with other researchers (n=7), and removal of duplicates, 2,649 titles were screened. Results of the literature search are presented in figure 1 , reported according to PRISMA [15] . Eighteen original studies were identified, including three placebo-controlled doubleblind trials [16] [17] [18] , a non-placebo controlled randomised trial [19] , a non-randomised trial [20] , an observational cohort [21] , and 12 uncontrolled studies and surveys [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] .
The efficacy of homeopathic medicinal products
The efficacy of homeopathic medicinal products prescribed for patients suffering from diagnosed depression was assessed in three RCTs (table 1) [16] [17] [18] .
In the most recently published placebo-controlled double-blinded double-dummy trial, the efficacy of individualised HMPs was compared to fluoxetine and placebo in 133 menopausal women suffering from moderate to severe diagnosed depression [18] . All women underwent a full consultation with a homeopath who prescribed an individually adapted HMP, with follow-up consultations at 4 and 6 weeks. Patients received either an HMP plus a placebo for fluoxetine (n=44); fluoxetine and placebo for an HMP (n=46); or placebo for both (n=43). HMPs were prescribed daily in liquid C30 or C200
potency. Fluoxetine-hydrochlorine 20 mg was increased to 40 mg after 4 weeks in case of nonresponse. The intention-to-treat analysis showed a 5.0 point difference in favour of HMPs compared to placebo, measured on the 17-item Hamilton Rating Scale for Depression (HRSD) at 6 weeks (p<0.001). Fluoxetine was better than placebo by 3.2 points (p<0.001). Results were clinically significant (minimum 3.0 points). Differences between homeopathy and fluoxetine were nonsignificant (p=0.082). Response rates (min. 50% HRSD decrease) at 6 weeks were better for homeopathy (54.4%) and fluoxetine (41.3%), compared to placebo (11.6%) (p<0.001), whereas differences in remission rates (min. 7 point HRSD reduction) were not statistically significant but not significantly superior to fluoxetine. Fluoxetine was not significantly better than placebo. There were no serious adverse events due to homeopathy. The prevalence of non-serious adverse events was similar in the three groups and included insomnia (n=6, 13.6%), dyspepsia (n=6, 13.6%), nausea (n=5, 11.4%), fatigue (n=5, 11.4%), anxiety (n=4, 9.1%), dizziness (n=4, 9.1%), diarrhoea (n=3, 6.8%),
headache (n=3, 6.8%), and constipation (n=2, 4.5%). The study was well described, it included a sample size calculation and multiple imputation was used for missing data. The risk of bias was low (figure 2) and the trial had acceptable model validity (figure 3).
A non-inferiority placebo-controlled double-dummy trial included 91 participants diagnosed with acute moderate to severe depression receiving either individually prescribed HMPs (Q-potencies daily) together with a placebo for fluoxetine; or fluoxetine (20 mg daily, increased to 40 mg after 4
weeks if no response) together with a placebo for HMPs [16] . All patients underwent the same medical and homeopathic assessment. Both groups (homeopathy n=48, fluoxetine n=43) improved over time (p<0.001) on the Montgomery Åsberg Depression Rating Scale (MADRS), with no significant between group differences at 4 weeks (95% CI -6.95, 0.86, p=0.65) and 8 weeks (95% CI -6.05, 0.77, p=0.97). The pre-fixed margin of non-inferiority was (Δ) 1.45, which was 1/3-1/2 of the advantage of fluoxetine over placebo, and the minimum considered of clinical relevance. Secondary outcomes were also similar in the two groups, including response rates (min. 50% MADRS reduction) at 4 weeks (fluoxetine 63.9%, homeopathy 65.8%) and 8 weeks (fluoxetine 84.6%, homeopathy 82.8%); and remission rates (MADRS < 11) at 4 weeks (fluoxetine 47.2%, homeopathy 55.3%, p=0.42) and 8 weeks (fluoxetine 76.9%, homeopathy 72.4%, p=0.72). The sample size was sufficient to establish non-inferiority of homeopathy compared to fluoxetine. The trial was well described, although only percentages (and not numbers) were provided for secondary outcomes (response & remission rates). The trial had high risk of bias due to high attrition rates (40% in both trial arms), and acceptable model validity.
The third randomised placebo-controlled trial had low risk of bias, but recruited only 44 out of 228 participants and was therefore underpowered and statistical tests were not carried out [17] .
The effectiveness of treatment provided by homeopaths
The effectiveness of treatment provided by homeopaths was assessed in a non-placebo randomised controlled trial [19] , a non-randomised trial [20] , and an observational cohort [21] (table 2) .
In a non-placebo controlled randomised trial including 211 menopausal women with self-reported depression, the effectiveness of a standardised homeopathic medicinal product (Ignatia Homaccord
[Ignatia amara & Moschus moschiferus], Heel GmbH) (n=110) prescribed daily for all patients was compared to fluvoxamine (n=101) [19] . Reduction in scores in the two groups at 6 weeks were comparable when measured on the Hamilton Depression Rating Scale (HDRS) (homeopathy 61%, fluoxetine 58%), as well as the Beck Depression Inventory (BDI) (homeopathy 66%, fluoxetine 65%).
Response rates (min. 50% improvement) were also comparable (homeopathy 68%, fluoxetine 65%).
All between group differences were not statistically significant (p>0.05). Results must be interpreted with caution, due to methodological weaknesses resulting in high risk of bias. The trial had inadequate model validity as the intervention was not based on the 'like treats like' principle so a substantial number of homeopaths would not support the choice of intervention for this group of patients.
In an observational cohort study, 710 depressed patients' use of psychotropic drugs was assessed over a time period of 12 months (table 2) Results controlled for potential confounding factors and baseline characteristics, and were not affected by depression severity. Similarly, the rate of clinical improvement (HADS score < 9) was better in the GP-Ho group compared to the GP-CM group (OR 1.70, 95% CI 1.10-2.87, p=0.05), but not when comparing GP-Mx patients to GP-CM patients (OR 1.49, 95% CI 0.89-2.50, p=0.13). There was potential selection bias due to low participation rates (45%), although this was similar across all three groups and differences between participants and non-participants were comparable. Baseline between group differences in anxiety and depression severity and history of suicide attempt could explain some, but not all between group differences in outcomes. Model validity was uncertain.
A trial that was considered by the reviewers to be non-randomised, suggested the combination of cognitive behavioural therapy (CBT) and homeopathy, was more effective than placebo or either treatment alone [20] . Results should be interpreted with caution due to high risk of bias (figure 4) and model validity was uncertain as it could not be assessed (figure 5).
Outcomes during and after treatment provided by homeopaths
Eleven uncontrolled studies (table 3) reported outcomes in a total of 595 patients (median 33, range 22-201) during or after treatment provided by homeopaths, including eight prospective uncontrolled
studies [23, [26] [27] [28] [29] [31] [32] [33] , three surveys [24, 25, 30] , and a retrospective case series [22] . Studies were highly heterogeneous and could only to a limited extent be presented in an aggregated form.
Six uncontrolled studies and surveys included 391 depressed patients (median 43, range 28-201) who were subsets of larger patient groups with various diagnoses [24, 28, [30] [31] [32] [33] . Patient-reported numerical rating scales showed at least moderate improvement (+2, +3 or +4 on seven-and nine-point numerical rating scales) in 50% to 86% of patients (median 67%), and slight or no improvement in 7% to 50% of patients (median 22%) following individualised treatment provided by homeopaths.
The time point for outcome assessment varied considerably (e.g. from 6 months to 7 years after treatment start), thereby reducing the generalisability of results.
A study including 83 patients diagnosed with depression receiving individualised treatment provided by homeopaths showed significant improvements at 3, 6, 9 and 12 months on the 17-point Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), the Clinical Global Impression (CGI-1) and Clinical Global Improvement (CGI-2) (all at p=0.001) [29] . At 12 months, 75% to 100% improvement in HDRS scores was seen in 57.8% (n=48); 50% to < 75% improvement in 20.5%
(n=17); 25% to < 50% improvement in 2.4% (n=2); and 19.3% (n=16) did not experience a significant change. Results were better for moderately and severely depressed patients, compared to those suffering from mild depression.
A retrospective case series of 15 patients diagnosed with depression found statistically significant improvements on the Montgomery Åsberg Depression Rating Scale (MADRS) at the 2 nd (mean 7 weeks) and 3 rd (14.5 weeks) consultation (p<0.001) [22] . A minimum improvement of 50% was found in 14 out of 15 patients by the 3 rd consultation.
The remaining four titles included two small prospective studies, one with marked improvement in more than half the patients using the SF-36 wellbeing questionnaire at 12 months [23] , a second with improvement in depression in almost three quarters of patients after at least 2 months [26] , and a third with 10% to 100% improvement in depression severity after at least 2 months [25] . Results of the last study are presented in the safety section [27] .
All uncontrolled studies have a high risk of selection, performance and detection bias, as there are no control groups and there is no blinding of patients, practitioners and assessors (figure 6). Risk of reporting bias was considered to be low for most studies [22] [23] [24] [25] [26] 28, [30] [31] [32] [33] . Only two studies had low risk of attrition bias and other forms of bias [22, 29] . The remaining studies only provided limited information about depression and used outcome measures not validated for depression, therefore leading to uncertain risk of attrition bias and other forms of bias. A single study was considered to
have acceptable model validity [22] and one had inadequate model validity [27] (figure 7). The remaining had overall uncertain model validity as each of these had at least one unclear key domain (rationale, principles, appropriate and sensitive outcome measure).
Safety of homeopathic medicines and treatment by homeopaths in depression
Four controlled trials [16] [17] [18] [19] , a cohort study [21] , and nine uncontrolled studies provided data relating to the safety of homeopathy [22] [23] [24] 27, [29] [30] [31] [32] [33] . No serious adverse events were reported according to NIH/NCI criteria (2010).
Adverse events in the homeopathy and fluoxetine groups were comparable in three placebo-controlled double-blinded trials [16] [17] [18] . No patient needed to interrupt treatment due to adverse events [18] , or adverse events were more common in the fluoxetine (21.4%) than the homeopathy (10.7%) group [16] ; more patients discontinued treatment due to adverse events in the fluoxetine (n=8) than the homeopathy (n=3) group; and a greater number of patients randomised to homeopathy (n=5) than fluoxetine (n=1) were excluded from the trial as a result of an intensification of depressive symptoms.
However, these trials were not powered to assess adverse effects and differences were not statistically significant. The cohort study did not detect statistically significant differences in the prevalence of self-reported injuries (GP-Ho 9.5%, GP-Mx 7.1%, GP-CM 14.8%) or suicide attempts (GP-Ho 1.5%, GP-Mx 1.9%, GP-CM 5.0%) [21] . In the non-placebo RCT, the standardised HMP was better tolerated than fluvoxamine, but no significance tests were presented [19] .
One uncontrolled study identified mild to moderate adverse events in 26% (n=9) of patients [27] . Four studies did not identify any adverse events [29] , or any deterioration of health [30] [31] [32] , whereas others reported one [22, 24] , or two patients with slight deterioration [33], or three that were not better or worse [23] .
In summary, few adverse events or cases of deteriorated state of health were reported and there was no evidence to suggest that treatment provided by homeopaths for patients suffering from diagnosed or self-reported depression was unsafe.
DISCUSSION
This systematic review adds 17 original research studies to a previous systematic review [7] , and includes only one title identified in the previous review. This updated review adds to the evidence of the efficacy of HMPs and changes in patient-reported outcomes following treatment provided by homeopaths. We cannot exclude the possibility that some studies have been overlooked particularly as
we excluded conference abstracts from our search strategy. However, we reduced the risk of betweenstudies publication bias through the use of several large generic databases and smaller homeopathyand CAM-specific databases, by not setting any language limitations, and by contacting experts in the field in 19 countries. We consider it less likely that results of unidentified studies would significantly affect the overall results, as the results for non-English studies and studies published in non-peerreviewed journals suggested comparable results.
The review used a novel approach to the assimilation of evidence by considering three different types of evidence: those assessing the efficacy of HMPs; those assessing the effectiveness of treatment by homeopaths; and those describing the outcomes of patients treated by homeopaths.
A weakness of the overall evidence is the limited extent to which aggregated results can be presented due to the heterogeneity of studies. Placebo-controlled RCTs can help answer the question of whether a specific part of an intervention, in this case HMPs, are effective to treat depression. Pragmatic RCTs and cohort studies can be used to test the effectiveness of the "whole treatment package", in this case treatment provided by homeopaths for depressed patients. The evidence from two placebo-controlled double-blinded trials, one with high and another with low risk of bias, suggests that homeopathic medicines may be non-inferior to fluoxetine. These findings are supported by two studies assessing the effectiveness of treatment by homeopaths; an observational study of GPs which found less use of psychotropic drugs and improved results for patients consulting with GPs prescribing HMPs, and a non-placebo RCT suggesting that the effectiveness of a standardised homeopathic medicine is comparable to the effectiveness of an antidepressant. The results of these non-blinded studies must be interpreted with caution as they were associated with high risk of bias. However, a single placebocontrolled trial with low risk of bias found homeopathic medicines were superior to placebo and the results were clinically significant.
The lack of controls and randomisation in uncontrolled studies precludes any conclusions about the effectiveness of interventions, but provides evidence of patient-reported outcomes following treatment by homeopaths. Most uncontrolled studies were small and had limitations reducing the reliability of results: high or unclear risk of detection, reporting and attrition bias due to no use of blinded assessors, insufficient information on drop-out and non-responders, and with the exception of two studies, outcome measures had not been validated for depressed patients. Strengths of uncontrolled studies were that all except one referred to patients with a diagnosis of depression, and described their reported changes in depression symptoms in "real world" practice [35] . Results showed at least moderate improvement in most patients in 10 out of 12 studies, whereas one only reported changes in symptoms and the other only adverse events. Model validity was uncertain or inadequate for all Such results would also need to be carried out in different groups of patients, including different depression severity groups (mild, moderate and severe depression), different age groups (e.g. adolescents, elderly), and patients with various comorbidities (e.g. pain, cancer), if results are to be generalised to different populations of depressed patients. Moreover, pragmatic RCTs are needed in order to test the effectiveness and cost-effectiveness of the "whole treatment package" provided by homeopaths, including consultations and medication, compared to commonly used interventions such as consultations with psychologists or with GPs who prescribe antidepressants.
Although some authors report up to moderate effect sizes of psychological interventions compared to waitlist or usual care controls for patients with depression [e.g. 37], the "true" effect is commonly overestimated [e.g. 38], and some authors found no significant differences when comparing "talking therapies" such as psychotherapy to antidepressants, or when comparing combinations of psychotherapy and antidepressants to antidepressants alone [34] . No RCTs comparing the effectiveness of the "whole treatment package" including consultations and individually adapted medication provided by homeopaths to usual care were identified in the review. This research is
required in order to assess the effectiveness of homeopathy in "real world practice" as an alternative or an adjunctive intervention to "talking therapy" interventions and antidepressant treatment.
The risk benefit ratio should also be considered for clinical decision making. Transient mild to moderate adverse events were identified. Although the studies included in our depression review were not powered to assess adverse events, there was no evidence to suggest the intervention was unsafe.
Further sufficiently powered research should look into the safety of homeopathic treatment.
CONCLUSIONS
The existing limited research evidence suggests that the effectiveness of homeopathic medicinal products for depressed patients is comparable to some antidepressants and superior to placebo, with clinically significant effects. A significant proportion of patients report improvements in depression following treatment provided by homeopaths in uncontrolled studies and surveys. No evidence suggested treatment was unsafe. However, further research is still needed to test the efficacy of homeopathic medicinal products, the effectiveness of treatment provided by homeopaths, and the safety of the intervention.
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